Aptinyx, which is developing novel small molecule therapeutics for neurological disorders, raised $102 million by offering 6.4 million shares at $16, the high end of the range of $14 to $16. The company originally planned to offer 5.3 million shares. Existing investors intended to buy up to $30 million on the IPO, representing 29% of the deal.
Aptinyx plans to list on the Nasdaq under the symbol APTX. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as lead managers on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.